We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Statins Reduce Risks of Heart Patients in Hospital

By HospiMedica staff writers
Posted on 05 Jun 2006
Patients who begin aggressive statin therapy while in the hospital for acute coronary syndromes (ACS) have a significantly greater chance of long-term survival, according to
a new study. More...


Combining data from nine randomized clinical trials and evaluating clinical outcomes individually rather than in combination, researchers from the Cleveland Clinic Foundation (OH, USA) examined data from more than 16,000 hospital-admitted patients with ACS, a term that encompasses both unstable chest pain (angina) and a particular form of heart attack. In each of the original studies, patients were randomly assigned to either maximal-dose statin therapy during the hospital stay or to a more conservative approach that consisted of low-dose statin therapy or a placebo.

Early, aggressive statin therapy reduced the risk of death by 22% and the risk of cardiovascular death by 25%, over a follow-up period that averaged 15 months. Further analysis showed that for every 111 patients who were treated with early statin therapy, one life could be saved. Early statin therapy also reduced the risk of another episode of unstable angina by 17% and the need for revascularization or coronary bypass surgery by 9%. The improvement in survival was noticeable early on but became statistically certain only after six months of statin therapy. The study was presented at the annual meeting of the Society for Cardiovascular Angiography and Interventions in Chicago (IL, USA) in May 2006.

"We found that there was a benefit in what matters most--survival,” said lead author Dr. Anthony Bavry, a fellow in cardiovascular medicine at the Cleveland Clinic Foundation. "The benefits keep accruing; once a patient has acute coronary syndrome, there may not be a safe time to discontinue this medication.”

Statins are primarily used to lower cholesterol levels in the blood, but they have other effects as well, including the ability to reduce inflammation in the arteries.



Related Links:
Cleveland Clinic Foundation

Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Heavy-Duty Wheelchair Scale
6495 Stationary
Infant Resuscitator
Easypuff
Radiology System
Riviera SPV AT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.